Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers compared regimens prescribed to pregnant women in their second trimester.
Findings suggest exposure to antiretrovirals, including dolutegravir, during pregnancy does not raise the risk of neural tube defects.
The latest revision recognizes the importance of treatment as prevention.
The integrase inhibitor–based HIV regimen was compared with dolutegravir-based regimens.
Researchers at George Washington University take a look.
The World Health Organization recommends this highly effective antiretroviral for all population groups, including young women.
The Food and Drug Administration has approved a new treatment for people living with HIV.
In clinical trials, the single-tablet regimen of Tivicay (dolutegravir) and Epivir (lamivudine) was as effective as a three-drug treatment.
Full 48-week results comparing dolutegravir plus lamivudine with a three-drug combo were presented at the International AIDS Conference.
A large ongoing study in Botswana has found that about 1 in 150 babies exposed to Tivicay at conception developed such birth defects.
The combo of dolutegravir and lamivudine controlled HIV as well as a triple-drug combo of dolutegravir plus Truvada.
Juluca is a single-tablet regimen for HIV.
Clinicians have presented a pair of case reports of patients going on the HIV medication and experiencing severe mental health reactions.
Two large trials switched participants from three- or four-drug combos to a regimen of Tivicay (dolutegravir) and Edurant (rilpivirine).
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.